Neil Carragher is Professor of Drug Discovery at the University of Edinburgh, he graduated from the University of Aberdeen, Scotland UK in 1992 with a B.Sc Honours degree in the subject of “Cell and Immunobiology”. He then took up a position within industry at the Yamanouchi Research Institute, Oxford, England UK where he also gained his PhD. He then held consecutive postdoctoral positions within the Department of Pathology, University of Washington, Seattle, USA and at the Beatson Institute for Cancer Research, Glasgow, Scotland UK. In 2004 Neil returned to the pharmaceutical industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca where he pioneered early multiparametric high-content phenotypic screening approaches.
In 2010 he once again made the career switch from industry to academia and took up the post of Principal Investigator of Drug Discovery at the University of Edinburgh where he leads a research group and is currently co-director of the Edinburgh Cancer Discovery Unit and the Edinburgh Phenotypic Assay Centre.
Primary research interests include advancing High-content analysis, phenotypic screening, Reverse Phase Protein Array technology, drug combinations and cancer drug discovery. Neil is also Chief Scientific Officer of the Phenomics Discovery initiative, a public-private consortia to advance phenotypic screening technologies https://npsc.ac.uk/pdi and is a founding member of the European Cell Based Assay Interest group www.eucai.org and global RPPA society.